Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS IG subpoenas Procrit documents

Executive Summary

Johnson & Johnson is responding to a subpoena from HHS' Office of Inspector General for documents related to the sales and marketing of the anemia treatment Procrit (epoetin alfa). The company said it received the subpoena Sept. 30 and is cooperating in responding to it. Procrit marketing is also under scrutiny by New York Attorney General Eliot Spitzer (1"The Pink Sheet" DAILY, Aug. 5, 2004)...

You may also be interested in...

J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation

Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.

California Federal Court Rejects Settlement Proposal In Coppertone ‘Mineral-Based’ Sunscreen Case

Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.

QUOTED. 11 May 2021. Phil Brown.

The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. See what Phil Brown, regulatory director of the Association of British HealthTech Industries, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts